Date: 2017-04-25
Type of information: Nomination
Compound:
Company: Quantum Genomics (France)
Therapeutic area: Cardiovascular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 25, 2017, Quantum Genomics announced the appointment of Dr Bruno Besse as the Company's Chief Medical Officer. Dr Besse will be in charge of all patient-related clinical development, interactions with regulators,
and pharmacovigilance activities. He will also supervise patient stratification and the positioning of Quantum Genomics’ drug candidates. Bruno Besse has held numerous
positions in the Medical Affairs departments of companies in the pharmaceutical industry. In 2011, he was appointed Global Medical Officer in the Cardiology Division of BMS. Prior to that, he also served as Chief Medical Officer at Crossject, Aventis and Boehringer-Mannheim. Awarded his MD by University Paris-Sud (Paris XI), he also holds a post-graduate degree in Biostatistics and is a graduate of INSEAD.
Financial terms:
Latest news:
Is general: Yes
